Comprehensive analysis of citrate effects during plateletpheresis in normal donors

Charles D. Bolan, Sarah E. Greer, Stacey A. Cecco, Jaime M. Oblitas, Nadja N. Rehak, and Susan F. Leitman

BACKGROUND: Although plateletpheresis procedures are generally well tolerated, the clinical and metabolic consequences associated with rapid infusion of up to 10 g of citrate are underappreciated, and a comprehensive description of these events is not available.

STUDY DESIGN AND METHODS: Clinical and laboratory changes were studied in seven healthy donors undergoing three 90-minute plateletpheresis procedures each, at continuous, fixed citrate infusion rates of 1.1, 1.4, and 1.6 mg per kg per minute.

RESULTS: Serum citrate levels increased markedly with increasing citrate infusion rates and did not achieve a stable plateau. As citrate infusion rates increased, the total volume processed and platelet yields also increased, but donor symptoms became more severe. Ionized calcium (iCa) and ionized magnesium (iMg) concentrations decreased markedly, by 33 and 39 percent below baseline, respectively, at a citrate rate of 1.6 mg per kg per minute. Intact parathyroid hormone levels were higher at 30 minutes than at later time points, despite progressive decreases in iCa and iMg. Urine citrate, calcium, magnesium, sodium, and potassium concentrations and urine pH values increased markedly during all procedures.

CONCLUSION: Marked, progressive increases in serum citrate levels occur during plateletpheresis, accompanied by symptomatic decreases in iCa and iMg, with significantly increased renal excretion of calcium, magnesium, and citrate.

ABBREVIATIONS: CIR(s) = citrate infusion rate(s); iCa = ionized calcium; iMg = ionized magnesium; iPTH = intact PTH; Pi = inorganic phosphorus; PTH = parathyroid hormone; WB:AC = whole blood to anticoagulant; WBFR(s) = whole-blood flow rate(s).

From the Departments of Transfusion Medicine and Laboratory Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland; and the Walter Reed Army Institute of Research, Silver Spring, Maryland.

Address reprint requests to: Charles D. Bolan, MD, Department of Transfusion Medicine, National Institutes of Health, Building 10, Room 1C711, 10 Center Drive, MSC 1184, Bethesda, MD 20892-1184; e-mail: cbulan@mail.cc.nih.gov.

The views expressed here are those of the authors and are not to be construed as the official position of the United States Department of Health and Human Services, the United States Public Health Service, the Department of Defense, or the United States Army.

Received for publication February 5, 2001; revision received April 22, 2001, and accepted April 24, 2001.

TRANSFUSION 2001;41:1165-1171.
symptoms remain an important limitation to procedure flow rates and thus to component yields. To more fully characterize citrate responses, we performed a pilot study in normal donors undergoing standard plateletpheresis procedures at three different, commonly used citrate infusion rates.

MATERIALS AND METHODS

Donors
Study subjects were healthy volunteer platelet donors chosen to provide a representative distribution of sex and weight. Donors met AABB eligibility criteria for plateletpheresis donation and gave informed consent for participation in the study. Subjects were required to have bilateral peripheral venous access and normal liver and renal function tests. Donor blood volumes were calculated by sex, height, and weight as described previously.2

Plateletpheresis procedures
Procedures were performed with the use of a continuous-flow blood cell separator (CS-3000 Plus, Baxter Healthcare, Deerfield, IL) using ACD-A (Baxter) containing 21.3 mg per mL of citrate as trisodium citrate and citric acid.3 Donors underwent three procedures each, during which constant citrate infusion rates of 1.1, 1.4, and 1.6 mg per kg per minute were used, with at least 4 weeks between successive procedures. The first plateletpheresis procedure was performed to define the metabolic changes associated with a citrate infusion rate of 1.6 mg per kg per minute. Because of the unexpectedly profound changes observed, two additional procedures were performed, at 1.1 and 1.4 mg per kg per minute, in random order, to more clearly define the dose relationship between citrate and its metabolic effects. Whole-blood flow rates (WBFRs) and ratios of whole blood to anticoagulant (WB:AC) were maintained throughout each plateletpheresis procedure at values determined in advance to characterize citrate responses, we performed a pilot study in normal donors undergoing standard plateletpheresis procedures at three different, commonly used citrate infusion rates.

Laboratory analysis
Blood samples for laboratory analysis were obtained from a sterile port placed on the apheresis withdrawal line 5 inches from the anticoagulant port. Samples were obtained at 0 (baseline), 30, 60, and 90 minutes into the procedure. Samples were collected anaerobically and sent immediately for analysis of serum iCa, iMg, and pH with the use of an electrolyte analyzer (AVL988-4, AVL Scientific, Roswell, GA). Serum and urine citrate levels were measured enzymatically with an analyzer (COBAS FARA, Roche Diagnostics Systems, Montclair, NJ) by use of a commercial kit (Boehringer Mannheim, Mannheim, Germany). The imprecision of the method for measurement of citrate (mean; CV%) was 1.04 mmol per L (1.77 percent) and 2.13 mmol per L (1.09 percent), respectively. Another analyzer (Hitachi 917, Roche Diagnostics, Indianapolis, IN) was used to analyze total calcium, total magnesium, and other electrolytes. Citrate at 5 mmol per L did not interfere with measurements of these values. Plasma samples for intact PTH (iPTH) were analyzed by using a chemoluminescence immunoassay (IMMULITE, Diagnostics Products Corp., Los Angeles, CA). The imprecision of the iPTH method (mean; CV%) was 63 ng per L; 4.3 percent and 447 ng per L; 6.4 percent. Urine electrolytes and creatinine were determined with the use of a clinical system (Synchrom CX9 ALX, Beckman Coulter, Brea, CA). Serum and urine phosphorus were measured as inorganic phosphorus (Pi) in mg per dL. Other electrolytes were measured in mmol per L. Urine samples were obtained immediately before (baseline) and after plateletpheresis. Urine electrolyte excretion was estimated by calculating the ratio of urine electrolyte and urine creatinine.

Donor symptom assessment and management
Donor symptoms such as paresthesias, cramping, nausea, and other complaints were assessed by experienced apheresis nurses as “0” if none, “1” if barely noticeable, “2” if irritating, “3” if uncomfortable, and “4” if unbearable. For symptoms that were ≥2, the citrate infusion rate was reduced 16 percent by decreasing the whole blood processing rate by a corresponding amount. The procedure was interrupted for symptoms that were ≥3.

Statistical analyses
Graphs and statistical comparisons were performed with a statistical application (Excel, Microsoft, Redmond, WA). Comparisons of results obtained at different citrate infusion rates for subjects undergoing otherwise identical procedures were made by using a two-tailed, paired t test. Percentage changes in the concentrations of serum and urine analytes were calculated by using 100 percent as the baseline concentration. The iCa and iMg fractions were calculated as follows:

\[
FiCa = \frac{[iCa]}{[tCa]},
\]

and

\[
FiMg = \frac{[iMg]}{[tMg]},
\]

where FiCa = the fraction of iCa, and FiMg = the fraction of iMg.

RESULTS

Donor demographics and responses
Four men and four women consented to participate in the study. One woman withdrew because of inconvenience, af-
ter one donation at a citrate infusion rate (CIR) of 1.6 mg per kg per minute, during which she experienced Level 3 symptoms. The demographics, volume processed, and component yields for the seven donors completing the study are shown in Table 1. Subjects were experienced plateletpheresis donors, with a mean of 62 (median, 46; range, 3-247) prior donations. The mean initial whole-blood processing rates were 57 mL per minute at a CIR of 1.6 mg per kg per minute, 54 mL per minute at 1.4 mg per kg per minute, and 47 mL per minute at 1.1 mg per kg per minute. The volume processed over 90 minutes increased significantly with higher CIRs, as they resulted in higher WBFRs. Similarly, the platelet yield increased significantly at CIRs of 1.4 and 1.6 mg per kg per minute, as compared to the yield at 1.1 mg per kg per minute (p<0.002). The mean (range) infusion rate of anticoagulant, expressed as milliliters of ACD-A per liter of estimated donor blood volume per minute at each weight-based CIR, was 0.82 (0.72-0.91) at 1.1, 1.05 (0.96-1.16) at 1.4, and 1.15 (1.06-1.21) at 1.6 mg per kg per minute.

There was a trend toward more severe citrate-related symptoms at the highest CIR (Table 2). Two donors experienced citrate-related symptom scores of 3 at a CIR of 1.6 mg per kg per minute, one had a symptom score of 3 at 1.4 mg per kg per minute, and no donors had scores of 3 at 1.1 mg per kg per minute. Similarly, three donors were asymptomatic at a CIR of 1.1, while none was asymptomatic at 1.4 mg per kg per minute, and only one was asymptomatic at 1.6 mg per kg per minute.

Changes in laboratory values

The levels of iCa and iMg fell progressively without reaching a plateau (Fig. 1A). Levels were significantly lower at each 30-minute interval than at the prior interval, so that nadirs universally occurred at 90 minutes (Table 3). Mean nadirs, in mmol per L (% change from baseline), were 0.95 (–23%) at 1.1, 0.86 (–30%) at 1.4, and 0.80 (–33%) at 1.6 mg per kg per minute for iCa and 0.43 (–26%) at 1.1, 0.35 (–37%) at 1.4, and 0.32 (–39%) at 1.6 mg per kg per minute for iMg. Mean iCa and iMg nadirs were significantly lower with each incremental increase in the CIR (Table 3).

Serum citrate levels increased continuously during plateletpheresis, without reaching a plateau. Higher CIRs were associated with significantly higher serum citrate levels at every interval at which they were measured (Fig. 1B), with peak citrate concentrations achieved at 90 minutes (Fig. 2). Serum iCa, iMg, FiC, and FiMg showed a strong negative correlation with increasing serum citrate levels (Fig. 2). In contrast, iPTH levels were highest at 30 minutes, despite continued declines in iCa levels at 60 and 90 minutes (Fig. 3).

Additional changes in serum laboratory results that were observed at the completion of plateletpheresis are shown in Fig. 4. Mean serum phosphorus levels decreased by 31 percent. Significant, but more modest, changes were also observed in serum total calcium (3% decrease), sodium (1% increase), potassium (6% decrease), and bicarbonate (3% increase). Mean serum pH increased from 7.40 to 7.42. No significant change was observed in total serum magnesium (1% decrease; p = 0.42). At the completion of plateletpheresis, the mean values for these analytes remained within the normal reference range, except for the phosphorus concentration (mean, 2.0 mg/dL; reference range, 2.3–4.3 mg/dL). There was no clear association between changes in the serum concentration of these analytes and changes in serum citrate concentration or CIRs.

The effect of the administration of citrate anticoagulant preservative solution on changes in the concentrations of urine analytes is shown in Fig. 5. The calculated analyte:creatinine ratios for citrate, calcium, and magnesium were markedly greater in urine samples collected immediately after plateletpheresis than in those collected just before plateletpheresis. The mean ratio for citrate increased by 2200 percent, that for total calcium by 310 percent, that for magnesium by 90 percent, that for sodium by 200 percent, and that for potassium by 260 percent. The mean urine pH also increased from 5.6 before plateletpheresis to 7.6 immediately after plateletpheresis, which corresponded to a 99-percent decrease in urinary hydrogen ion concentration. The effect of an increased urine citrate concentration on urine molar ratios (cation:citrate [both mmol/L]) for calcium, magnesium, sodium, and potassium is shown in Table 4.
We demonstrated that rapid, continuously increasing serum citrate levels occur during plateletpheresis procedures in healthy donors and that these increased citrate levels are associated with mean peak reductions of up to 33 percent in iCa and 39 percent in iMg at the end of the procedure. Both the pace and magnitude of the decreases in ionized divalent cation levels were directly correlated with increasing CIRs. Furthermore, the frequency and severity of donor symptoms were closely associated with greater CIRs and higher serum citrate levels.

All three CIRs used in this study were within the recommended guidelines of the apheresis device manufacturer, and they spanned the range commonly used during plateletpheresis but were associated with continued and progressive accumulation of serum citrate. Significantly greater processed volumes and component yields were obtained at the faster processing rates, but they were accompanied by progressive decreases in ionized divalent cation levels as serum citrate increased. Although donor symptoms were variable in this small cohort, the severity of citrate symptoms increased with increasing CIRs, and 33 percent of donors experienced uncomfortable muscle cramps and paresthesias at the greatest CIR. The decreases in iCa and iMg, and the increases in serum citrate levels and quantities of citrate administered during these procedures approach levels observed in massive transfusion during liver transplantation.13,14

When ionized divalent cation levels were expressed as a fraction of total levels (FiCa, FiMg), the fractional decrease also exhibited a strong negative correlation with serum citrate levels. This finding has implications for the use of prophylactic supplemental oral or IV calcium, because, at a given serum citrate concentration, an increase in total serum calcium levels would be expected to lessen the absolute decrease in ionized levels.

In contrast to the constant, negative correlation between iCa and iMg and the progressive changes in serum citrate levels, changes in iPTH did not parallel the course of changes in those values. Levels of iPTH peaked early in plateletpheresis and then declined, despite further decreases in iCa. Furthermore, because peak iPTH responses occur as early as 5 to 10 minutes after the initiation of citrate-induced hypocalcemia,15 the maximal iPTH level probably occurred before the first 30-minute samples were obtained in this study.10 While previous studies have examined changes in the c-terminal and...
n-terminal regions of PTH, changes in iPTH may more accurately reflect physiologic responses. Although markedly increased iPTH levels have previously been noted during plateletpheresis, the relationship of these changes with controlled variations in CIRs was not examined until the present study. Our observations support the view that iPTH is released from the parathyroid gland as an initial bolus, which is followed by tonic secretion. The fact that we observed no significant difference in peak or subsequent iPTH levels during procedures performed at different CIRs suggests that the threshold for maximal release of iPTH is exceeded during routine plateletpheresis. It is also possible that the need for further PTH release is modified by the contribution of other compensatory mechanisms.

Serum phosphorus levels decreased markedly during plateletpheresis, with nadirs significantly below the normal range. Significant but more modest changes were observed in other serum analytes, with values at the end of plateletpheresis remaining within normal limits. Total calcium and potassium levels decreased by 3 and 6 percent, while serum sodium and bicarbonate increased by 1 and 3 percent, respectively. Similarly, serum pH increased from 7.40 to 7.42. No significant change was observed in total magnesium levels. In contrast to the changes in ionized divalent cation concentrations, changes in those values did not ex-
hibit a clear association with serum citrate concentrations or changes in CIRs. These events may reflect the interactions of multiple compensatory mechanisms, such as hepatic and renal metabolism of citrate to bicarbonate, sustained increases in iPTH, and physiologic responses to the acute dextrose and sodium load infused as part of the anticoagulant solution.

We observed that plateletpheresis was accompanied by striking increases in urinary pH and urinary excretion of citrate, total calcium, total magnesium, sodium, and potassium, as measured in urine samples obtained at the beginning and end of each procedure. Paradoxically, the increased urinary excretion of calcium and magnesium occurred at a time when serum ionized divalent cation levels were markedly decreased and compensatory mechanisms for cation conservation, such as PTH release, should have been maximized. In agreement with prior observations that urinary iCa levels decrease after plateletpheresis, we showed that urinary calcium and magnesium concentrations were much greater than urinary citrate concentration before plateletpheresis, while urinary citrate concentration increased in the ratio when measured against urinary calcium and magnesium concentrations after plateletpheresis. Our data suggest that renal excretion of an acute citrate load is associated with an obligate increase in cation excretion during plateletpheresis that cannot be overcome by the body's compensatory mechanisms. Sodium and potassium excretion also increased after plateletpheresis, which may reflect citrate's metabolism to bicarbonate and/or the delivery of sodium and dextrose with the infusion of the anticoagulant solution.

The aggregate data in this study provide new information about changes that occur during plateletpheresis and clarify the time course of previously described events. These findings are consistent with observations that symptoms increase markedly and citrate levels continue to increase when CIRs >1.0 mg per kg per minute are used during plateletpheresis. While plateletpheresis is safe and well tolerated during most donations, this safety may be related to the fact that the procedures are completed, or modified because of donor symptoms, before the accumulation of toxic levels of citrate. Because higher CIRs must be used in lighter-weight donors during procedures performed at standard blood-processing rates, those donors will have more profound laboratory changes and associated symptoms. Oral or IV calcium administration in association with citrate infusions may provide a further level of donor comfort and permit increased component yields. Additional studies to ascertain the cumulative effects of these changes may be of benefit, particularly for frequent platelet donors.

ACKNOWLEDGMENTS
The authors thank Harvey Klein, MD, for helpful comments and manuscript review and the dedicated nurses and recruitment staff of the NIH Platelet Center: Rolande Grammont, Phyllis Byrne, Monica Riordan, Virginia Morgan, and Hal Wilkins.

REFERENCES
1. Lewisohn R. A new and greatly simplified method of blood transfusion. Med Rec 1915;87:141-2.
2. Hester JP, McCullough J, Mishler JM, Szymanski IO. Dosage regimens for citrate anticoagulants. J Clin Apheresis 1983;1:149-57.
3. Strauss RG. Mechanisms of adverse effects during hemapheresis. J Clin Apheresis 1996;11:160-4.
4. McLeod BC, Price TH, Owen H, et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998;38:938-43.

5. Mishler JM, Janes AW, Lowes B, et al. Utilization of a new strength citrate anticoagulant during centrifugal plateletpheresis. I. Assessment of donor effects. Br J Haematol 1976;34:387-94.

6. Huestis DW, Fletcher JL, White RF, Price MJ. Citrate anticoagulants for plateletpheresis. Transfusion 1977;17:151-5.

7. Olson PR, Cox C, McCullough J. Laboratory and clinical effects of the infusion of ACD solution during plateletpheresis. Vox Sang 1977;33:79-87.

8. Szymanski IO. Ionized calcium during plateletpheresis. Transfusion 1978;18:701-8.

9. Silberstein LE, Naryshkin S, Haddad JJ, Strauss JF 3d. Calcium homeostasis during therapeutic plasma exchange. Transfusion 1986;26:151-5.

10. Toffaletti J, Nissenson R, Endres D, et al. Influence of continuous infusion of citrate on responses of immunoreactive parathyroid hormone, calcium and magnesium components, and other electrolytes in normal adults during plateletapheresis. J Clin Endocrinol Metab 1985;60:874-9.

11. Mercan D, Bastin G, Lambermont M, Dupont E. Importance of ionized magnesium measurement for monitoring of citrate-anticoagulated plateletpheresis. Transfusion 1997;37:418-22.

12. Hester JP, Ayyar R. Anticoagulation and electrolytes. J Clin Apheresis 1984;2:41-51.

13. Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev 1988;2:76-94.

14. Diaz J, Acosta F, Parrilla P, et al. Serum ionized magnesium monitoring during orthotopic liver transplantation. Transplantation 1996;61:835-7.

15. Schmitt CP, Schaefer F, Bruch A, et al. Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium. J Clin Endocrinol Metab 1996;81:4236-43.

16. Bongiovanni MB, Strauss J 3d, Ziselman EM, Wurzel HA. Parathyroid response during therapeutic plasma exchange. Transfusion 1983;23:535-6.

17. Toffaletti J. Changes in protein-bound, complex-bound, and ionized calcium related to parathyroid hormone levels in healthy donors during plateletapheresis. Transfusion 1983;23:471-5.

18. Hamm LL. Renal handling of citrate. Kidney Int 1990;38:728-35.